1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector

RxCUI: 2058872
RxNorm name: 1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector
Display name: 1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector
Full name: 1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:53

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761063	Emgality	galcanezumab-gnlm	351(a)	Rx	2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
EMGALITY	GALCANEZUMAB-GNLM	Eli Lilly and Company	33a147be-233a-40e8-a55e-e40936e28db0	2026-06-05	Warnings, Adverse reactions	Exact identifier rxcui: 2058872

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
33a147be-233a-40e8-a55e-e40936e28db0	galcanezumab-gnlm 120 MG in 1 ML Auto-Injector [PSN] · 1 ML galcanezumab-gnlm 120 MG/ML Auto-Injector [SCD] · galcanezumab-gnlm 120 MG per 1 ML Auto-Injector [SY]	3	15	These highlights do not include all the information needed to use EMGALITY safely and effectively. See full prescribing information for EMGALITY. EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use Initial U.S. Approval: 2018	20251021